Barbara Claus1,2, Kaat De Pourcq3, Nele Clottens1, Vibeke Kruse4, Paul Gemmel3, Johan Vandenbroucke1. 1. Department of Pharmacy, Ghent University Hospital, Ghent, Belgium. 2. Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. 3. Faculty of Economics and Business Administration, Ghent University, Ghent, Belgium. 4. Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium.
Abstract
BACKGROUND: Dose banding (DB) (dose rounding with predetermined variation with prescription) enables in-advance preparation of high-turnover anticancer drugs with potential benefit for pharmacy compounding work flow. OBJECTIVES: To analyse the impact of potential situations on the efficiency of DB in the pharmacy (safe and maximum storage), calculate preparation lead times and the potential full-time equivalent (FTE) benefit. METHODS: Candidate intravenous anticancer drugs were selected for logarithmic DB according to prescribing frequency, infusion volume and stability (usage data 2015 of the tertiary Ghent University Hospital, Belgium). With a selected DB set already stored, a 2-week time study (April/November 2015) provided lead times (between prescription and transfer) for just-in-time and DB preparations. A 'maximal' storage (using all drugs with a relative incidence of ≥2% recurrent monthly prescription) and a 'safe' storage scenario (lowest monthly prescribing pattern) were used to calculate the potential future FTE change. RESULTS: Mean lead times for DB storage and just-in-time preparation were 17.1 min (95% CI 13.5 to 21.0) and 26.5 min (23.3 to 29.8). For 21 164 yearly preparations with already 5292 in DB (25%), 11 157 and 6 862 could be batch-produced in advance in a maximum storage and safe storage scenario, respectively. The existing FTE in 2015 of 5.41 could then be reduced to 4.91 and 5.27. CONCLUSION: Further development of DB could contribute to pharmacy compounding efficiency.
BACKGROUND: Dose banding (DB) (dose rounding with predetermined variation with prescription) enables in-advance preparation of high-turnover anticancer drugs with potential benefit for pharmacy compounding work flow. OBJECTIVES: To analyse the impact of potential situations on the efficiency of DB in the pharmacy (safe and maximum storage), calculate preparation lead times and the potential full-time equivalent (FTE) benefit. METHODS: Candidate intravenous anticancer drugs were selected for logarithmic DB according to prescribing frequency, infusion volume and stability (usage data 2015 of the tertiary Ghent University Hospital, Belgium). With a selected DB set already stored, a 2-week time study (April/November 2015) provided lead times (between prescription and transfer) for just-in-time and DB preparations. A 'maximal' storage (using all drugs with a relative incidence of ≥2% recurrent monthly prescription) and a 'safe' storage scenario (lowest monthly prescribing pattern) were used to calculate the potential future FTE change. RESULTS: Mean lead times for DB storage and just-in-time preparation were 17.1 min (95% CI 13.5 to 21.0) and 26.5 min (23.3 to 29.8). For 21 164 yearly preparations with already 5292 in DB (25%), 11 157 and 6 862 could be batch-produced in advance in a maximum storage and safe storage scenario, respectively. The existing FTE in 2015 of 5.41 could then be reduced to 4.91 and 5.27. CONCLUSION: Further development of DB could contribute to pharmacy compounding efficiency.
Entities:
Keywords:
Adult oncology; Compounding (individualised preparation); Shelf life; time management
Authors: C Bardin; A Astier; A Vulto; G Sewell; J Vigneron; R Trittler; M Daouphars; M Paul; M Trojniak; F Pinguet Journal: Ann Pharm Fr Date: 2011-08-03